miR-190和ANXA11对直肠癌新辅助放化疗效用评估价值及相关性分析

doi:10.3969/j.issn.1006-6233.2023.12.03

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1427 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the roles and relationship of microRNA 190 (miR-190) and membrane-associated protein A11 (ANXA11) in the evaluation of neoadjuvant radiotherapy (NAC) for rectal cancer. Methods: A total of 148 patients who were diagnosed with rectal cancer and received treatment in our hospital from June 2019 through August 2022 were selected as the study subjects and included in the rectal cancer group, and 150 healthy people who underwent general physical examination in our hospital during the same period were selected as the control group, and real-time fluorescence quantitative detection (RT-PCR) detected the expression of serum miR-190 and ANXA11 mRNA in the two groups. All rectal cancer patients were treated with the same neoadjuvant radiotherapy and chemotherapy (NAC) before surgery, and were divided into the excellent efficacy group (n=89) and the poor efficacy group (n=59) according to the efficacy assessment criteria, and the serum miR-190 and ANXA11 mRNA expression of the patients in the two groups were compared. Spearman's correlation coefficient was used to analyze the relationship between serum miR-190, ANXA11 mRNA expression and clinical efficacy; Kaplan-meier was plotted to observe the effect of high and low miR-190, ANXA11 mRNA expression on the clinical efficacy of NAC; Subject operating characteristic curves (ROCs) were plotted to analyze the value of miR-190, ANXA11 single and combined assays for clinical utility assessment of NAC. Results: Compared with the control group, miR-190 expression was significantly lower, while ANXA11 mRNA expression was significantly higher in rectal cancer patients (0.87±0.18 vs 1.53±0.30, 2.00±0.68 vs 0.95±0.09, t=-22.719, 18.731, P<0.05). Compared with the poor-efficacy group, miR-190 expression was significantly higher in patients in the excellent-efficacy group, while ANXA11 mRNA expression was significantly lower (0.96±0.15vs0.73±0.15, 1.81±0.47vs2.28±0.83, t=8.932, -3.958, all P<0.05); Spearman correlation coefficient analysis showed that miR-190 was positively correlated with NAC efficacy, while ANXA11 mRNA expression was negatively correlated with NAC efficacy (P＜0.05); Kaplan-meier curves showed that the NAC efficacy excellence rate of the patients in the miR-190 high-expression group was significantly higher than that of the patients in the miR-190 low-expression group (χ²=39.120, P＜0.001), and the excellent rate of NAC efficacy in patients in the ANXA11 mRNA low expression group was significantly higher than that in the ANXA11 mRNA high expression group (χ²=8.772, P=0.003); the ROC showed that the area under the curve (AUC) of the combined assay of miR-190 and ANXA11 was significantly higher than that of the single assay (P＜0.05), and the sensitivity was 84.75%, the specificity of 87.64%. Conclusion: miR-190 and ANXA11 have specific expression levels in patients with different NAC efficacy, and there is a close association between them and NAC efficacy. miR-190 and ANXA11 detection can effectively predict the clinical utility of NAC by combining miR-190 and ANXA11 assays, which can provide a new idea for the clinical assessment of rectal cancer efficacy.

Key words： Rrectal cancer miR-190 Membrane-bound protein A11

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.12.03 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I12/1946

[1] Wilkinson N.Management of rectal cancer[J].Surg Clin North Am,2020,100(3):615-628.
[2] Lang D,Ciombor KK.Diagnosis and management of rectal cancer in patients younger than 50 years:rising global incidence and unique challenges[J].Natl Compr Canc Netw,2022,20(10):1169-1175.
[3] Keller DS,Berho M,Perez RO,et al.The multidisciplinary management of rectal cancer[J].Nat Rev Gastroenterol Hepatol,2020,17(7):414-429.
[4] Vendrely V,Rivin Del Campo E,Modesto A,et al.Rectal cancer radiotherapy[J].Cancer Radiother,2022,26(1-2):272-278.
[5] Wang Z,Su C.Effects of folic acid deficiency on genetic damage in colorectal cancer cells[J].Am Transl Res,2023,15(5):3162-3171.
[6] Qi J,Wang Z,Zhao Z,et al.EIF3J-AS1 promotes glioma cell growth via up-regulating ANXA11 through sponging miR-1343-3p[J].Cancer Cell Int,2020,20(1):428.
[7] 中华人民共和国国家卫生和计划生育委员会.直肠癌规范化诊疗指南(试行)[J].慢性病学杂志,2013,14(10):721-726.
[8] Liu D,Langer R.Grading der Tumorregression gastrointestinaler karzinome nach neoadjuvanter therapie grading of tumor regression of gastrointestinal carcinomas after neoadjuvant therapy[J].Pathologe,2022,43(1):51-56.
[9] 潘驰,孙晓晖,张增智,等.2014-2020年青岛市居民结直肠癌流行及疾病负担趋势分析[J].中华肿瘤防治杂志,2022,29(20):1439-1445.
[10] Stoffel EM,Murphy CC.Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults[J].Gastroenterology,2020,158(2):341-353.
[11] Bachet JB,Benoist S,Mas L,et al.Traitement néoadjuvant des cancers du rectum Neoadjuvant treatment for rectal cancer[J].Bull Cancer,2021,108(9):855-867.
[12] Sun G,Liu M,Han H.Overexpression of microRNA-190 inhibits migration,invasion,epithelial-mesenchymal transition,and angiogenesis through suppression of protein kinase B-extracellular signal-regulated kinase signaling pathway via binding to stanniocalicin 2 in breast cancer[J].Cell Physiol,2019,234(10):17824-17838.
[13] Yu Y,Yin W,Yu ZH,et al.miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer[J].Exp Clin Cancer Res,2019,38(1):22.
[14] Yu Y,Luo W,Yang ZJ,et al.miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial-mesenchymal transition[J].Mol Cancer,2018,17(1):70.
[15] Ye R,Lu X,Liu J,et al.CircSOD2 contributes to tumor progression,immune evasion and anti-PD-1 resistance in hepatocellular carcinoma by targeting miR-497-5p/ANXA11 axis[J].Biochem Genet,2023,61(2):597-614.
[16] Liu Z,Wang Y,Wang L,et al.Long non-coding RNA AGAP2-AS1,functioning as a competitive endogenous RNA,upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma retracted in[J].Exp Clin Cancer Res,2022,41(1):317.